Director Cheng Guilin of the Department of Gastroenterology, together with several famous professors in China, declared that the national scientific and technological major special research project has been approved by the state. The state will allocate a considerable amount of special funds for the research of optimal treatment methods to reverse hepatic fibrosis cirrhosis and block the progression of hepatitis B disease. This clinical study will provide free treatment with nucleotides (entecavir dispersible tablets), interferon (Peroxyn) or thymidine (Zetaoxyn) to 1,000 patients nationwide who participate in the project. Patients participating in the free treatment for 1.5-2 years need to meet the following criteria: progressive liver fibrosis (stage S2/3 on liver biopsy); early cirrhosis (stage S4 on liver biopsy); and compensated cirrhosis (gastroscopy suggestive of variceal veins). There were 4 groups: 1. Entecavir group: 500 patients, 0.5 mg, orally once a night before bedtime 2. Entecavir combined with interferon treatment group: 190 patients with progressive cirrhosis (stage S2/3) were treated with entecavir 0.5 mg, orally once a night before bedtime, and after 6 months, combined with long-acting interferon 180 μg subcutaneously once a week for 1 year, and then continued with oral entecavir 0.5 mg once daily as monotherapy for 1 year, for a total of 2 years. 3. Entecavir combined with thymidine treatment group: 310 patients with early stage cirrhosis (S4 stage) or compensated cirrhosis were treated with entecavir 0.5 mg orally once a night before bedtime, followed by thymidine 1.6 μg subcutaneously twice a week after six months for 1 year, after which oral entecavir monotherapy was continued for 1 year for a total of 2 years. 4. Entecavir for cirrhosis group: Patients whose diagnosis of cirrhosis is supported by endoscopy and other imaging can be treated with entecavir 0.5 mg orally once a night before bedtime for one and a half years. There are 120 spots available in the gastroenterology department of our center, and the specific groupings need to be reported to the Beijing Clinical Research Center for randomization. Patients from Shanghai or other provinces who are interested in participating in the clinical study can contact the Director of Gastroenterology, Cheng Guilin. Emails can be sent to: [email protected] Specific criteria for enrollment: 1) Age between 18 and 65 years old (including 18 and 65 years old, at the time of signing the informed consent form); 2) Any gender; 3) Patients with chronic hepatitis B fibrosis/early cirrhosis and consent for pre- and post-treatment liver puncture or non-hepatic puncture-confirmed compensated hepatitis B cirrhosis primary patients; 4) Non- HBeAg-positive patients with HBV DNA >2×104 IU/ml or HBeAg-negative patients >2×103 IU/ml, and HBeAg-positive patients with HBV DNA >2×103 IU/ml or HBeAg-negative patients >2×102 IU/ml in cirrhotic patients. 5) Can be followed up regularly (1 time in 3 months by the study center for free blood sampling for liver function and virus); 6) Sign the written informed consent